Core Viewpoint - The company, Shanghai Kaisa Biotechnology Co., Ltd., has released its quarterly report for the first quarter of 2025, ensuring the accuracy and completeness of the financial information presented [2][3]. Financial Data - The financial statements for the first quarter of 2025 have not been audited [3]. - The company reported a net profit of 0 yuan for the merged entity prior to the merger, consistent with the previous period [6]. Shareholder Information - The company has completed the registration of 137,911,755 new shares issued to specific investors as of March 31, 2025 [5]. Audit Opinion - The financial statements are categorized as unaudited, indicating that they have not undergone an external audit process [6].

Financial Performance - The company's revenue for Q1 2025 reached ¥775,769,935.75, representing a 13.33% increase compared to ¥684,521,536.95 in the same period last year[4] - Net profit attributable to shareholders was ¥136,950,113.57, a 30.11% increase from ¥105,258,699.94 year-on-year[4] - Net profit for Q1 2025 was CNY 124,318,691.92, compared to CNY 106,857,611.48 in Q1 2024, representing an increase of 16.25%[19] - The operating profit for Q1 2025 was CNY 161,685,700.77, up from CNY 123,463,826.25 in Q1 2024, indicating a growth of 30.93%[19] - Total revenue for Q1 2025 reached CNY 775,769,935.75, an increase of 13.38% compared to CNY 684,521,536.95 in Q1 2024[18] - Earnings per share for Q1 2025 were CNY 0.23, compared to CNY 0.18 in Q1 2024, marking a 27.78% increase[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 59.36% to ¥87,489,386.91, down from ¥215,276,527.96 in the previous year[4] - Cash received from sales and services in Q1 2025 was CNY 701,043,331.96, an increase from CNY 649,158,049.17 in Q1 2024, reflecting a growth of 7.99%[23] - Total cash outflow from operating activities was $657,274,979.57, an increase from $537,266,390.20 in the previous period[24] - Cash and cash equivalents at the end of the period totaled $10,635,851,218.02, up from $4,795,218,006.40 at the end of the previous period[25] - The net increase in cash and cash equivalents was $5,449,886,504.90, contrasting with a decrease of $218,561,556.52 in the prior period[25] Assets and Liabilities - Total assets increased by 29.80% to ¥24,689,868,403.18 from ¥19,021,477,349.64 at the end of the previous year[5] - The company's total liabilities decreased to RMB 3,161,806,107.54 from RMB 3,531,118,757.92, indicating a reduction of about 10.5%[16] - The total current liabilities decreased to RMB 2,538,495,884.89 from RMB 2,917,855,546.03, a reduction of about 13.0%[16] - The company's cash and cash equivalents increased significantly to RMB 10,797,271,252.93 from RMB 5,346,793,890.23, representing an increase of about 102.3%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,060[8] - The company's equity attributable to shareholders increased by 52.64% to ¥17,563,815,224.81 from ¥11,507,005,495.25[5] - Total equity attributable to shareholders increased from CNY 11,507,005,495.25 to CNY 17,563,815,224.81, a growth of 52.73%[17] Research and Development - R&D investment totaled ¥60,550,596.03, up 35.21% from ¥44,784,258.67, accounting for 7.81% of revenue[5] - Research and development expenses for Q1 2025 were CNY 60,550,596.03, compared to CNY 44,784,258.67 in Q1 2024, representing an increase of 35.25%[19] Other Financial Metrics - The weighted average return on equity rose to 1.18%, an increase of 0.24 percentage points from 0.94%[4] - The basic and diluted earnings per share were both ¥0.23, reflecting a 27.78% increase from ¥0.18[4] - Non-recurring gains and losses amounted to ¥1,587,608.51 for the period[6] - Other comprehensive income for Q1 2025 was CNY 3,862,477.80, compared to a loss of CNY 2,075,953.82 in Q1 2024, indicating a significant turnaround[20]

凯赛生物公告，2025年第一季度营收为7.76亿元，同比增长13.33%；净利润为1.37亿元，同比增长 30.11%。 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月21日晚间， 凯赛生物 发布2024年年度报告。报告期内，公司实现 营业收入29.58 亿元，比上年同期上升39.91% ， 实现营业利润 5.52 亿元，比上年 同期上升21.41% ；归属于上市公司股东的净利润 4.89 亿元，比上年同期上升33.41%。 | 单位 | | --- | | . | | 리 | | 市种 . | | 人民币 . | | | | | 本期比上年 | | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 同期增减 | 2022年 | | | | | (%) | | | 营业收入 | 2, 957, 911, 554. 76 | 2, 114, 174, 868. 81 | 39. 91 | 2, 441, 103, 971. 54 | | 归属于上市公 | | | | | | 司股东的净利 | 488, 961, 919. 11 | 366, 524, 3 ...

Core Insights - The company reported a revenue of 2.958 billion yuan in 2024, representing a year-on-year growth of 39.91%, and a net profit of 489 million yuan, up 33.41% year-on-year [2] - The company plans to distribute a cash dividend of 4.00 yuan per 10 shares to all shareholders [2] Group 1: Business Performance - The company maintains a global leading position in long-chain dicarboxylic acid products, with significant sales growth driven by technological advancements and market expansion [2][3] - The production capacity of bio-based caprylic acid has significantly increased since the project commenced in Q3 2022, leading to improved operational rates and market share [3] - The company successfully launched a 10,000-ton bio-based piperidine project at the end of 2024, which has begun generating sales [3] Group 2: Strategic Developments - The company has entered into a strategic cooperation agreement with the Hefei government and China Merchants Group to leverage their strengths in policy guidance, application scenario development, and biomanufacturing technology innovation [4] - A new company focused on composite materials manufacturing has been established, and projects are accelerating in Hefei, indicating the establishment of a comprehensive industrial chain for bio-based materials [4] Group 3: Research and Development - The company plans to focus on the development of the bio-based polyamide market in 2025, with a factory for bio-based polyamide modification and Bio-PPA CFRT under construction in Hefei [5] - Research and development expenses for 2024 amounted to 233 million yuan, a year-on-year increase of 23.38%, accounting for 7.89% of total revenue, with significant progress in various R&D projects [5]

【SynBioCon】 获 悉，2025年4月19-20日，中国（海南）自由贸易试验区、国家全面深化改革开放试验区、国家生态文明试验区的重要城市三亚迎 来了一场盛会——生物经济50人论坛（三亚）。这场由深圳市华谷致远生物科技与产业研究院（下称"华谷研究院"）主办，招商三亚深海科技城开发有 限公司承办的论坛，在崖州湾科技城盛大开幕。 本次论坛以"海洋生物制造：重塑未来产业格局"为主题，不仅汇聚了国内200多位顶尖的"产、学、研、投、用"各界领导和专家，更搭建了为产业创新 发展提供战略思路与实践方案的高端平台。相信必将有力推动我国生物经济再上新台阶。 4月19日下午，论坛的预热会议——生物制造产业联盟第三次理事会率先召开，包括理事长单位、副理事长单位、理事单位以及特邀嘉宾在内共计50多 位代表参加。 会上重点围绕工信部国家生物制造业创新中心的建设问题展开讨论 ；会议期间还全面总结2024年联盟工作，并就 生物经济的形势、相 关政策、企业关注的重大问题 等进行深入探讨。 论坛的重要议程之一是 华谷研究院正式发布 2024生物制造产业蓝皮书 。这是华谷研究院联合国内相关机构，专门针对生物制造产业编撰的系统性报 告。该 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688065 证券简称：凯赛生物 公告编号：2025-020 一、 监事会会议召开情况 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日向全 体监事以邮件方式发出会议通知，并于 2025 年 4 月 21 日上午 10:00 以通讯会议的方 式召开第二届监事会第二十四次会议。本次会议由监事会主席张国华主持，会议应到 3 人，实到 3 人。本次会议的召集、召开符合《中华人民共和国公司法》（以下简称 "《公司法》"）《上海凯赛生物技术股份有限公司公司章程》等法律法规及规范性 文件的有关规定。 上海凯赛生物技术股份有限公司 第二届监事会第二十四次会议决议公告 （三）审议通过《关于 2024 年年度报告全文及摘要的议案》 监事会认为：公司 2024 年年度报告及摘要的编制和审议程序符合法律、行政法 规、公司章程和公司内部管理制度的各项规定；年度报告编制过程中，未发现公司参 与年度报告及摘要编制和审议的人员有违反保密规定的行为。公司严格按照上 ...

每股分配比例：A 股每股派发现金红利 0.4 元（含税），不送红股、 不以资本公积转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本扣除回购专用 证券账户中股份数为基数，具体日期将在权益分派实施公告中明确。在实施权益 分派的股权登记日前公司总股本扣除回购专用证券账户中股份数发生变动的，拟 维持每股分配比例不变，相应调整分配总额，并将另行公告具体调整情况。 上海凯赛生物技术股份有限公司 2024 年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司不会触及《上海证券交易所科创板股票上市规则》（以下简称《科 创板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能被实施其他风 险警示的情形。 证券代码：688065 证券简称：凯赛生物 公告编号：2025-022 一、利润分配方案内容 （一）利润分配方案的具体内容 截至 2024 年 12 月 31 日，公司母公司报表中期末未分配利润为人民币 1,359,496,713.01 元。经董事会决议，公司 2024 年年度拟以实施 ...

一直在路上，所以停下脚步，只在于分享 包括： 新 材料/ 半导体 / 新能源/光伏/显示材料 等 添加 小编微信 ，遇见 志同道合 的你 写在前面 （文末有惊喜） 正文 = 在 1 is fo 基础化工 点击 最 下方 "在看"和" "并分享，"关注"材料汇 行业专题 以生物造万物. 构建 Al+新质生产力新业态 合成生物深度系列报告之一 主要观点: ● 合成生物学是生产力转型升级新方向 合成生物学是一门基于工程化的设计理念,结合生物学、化学、医 学、农学、工程学、计算机与数据科学等交叉学科技术,旨在设计 和构建新的生物系统,以实现特定的功能,其本质是让细胞为人类 工作生产想要的物质。合成生物学和发酵工程的区别在于是否对细 胞进行定向性干预,大幅提升微生物细胞工厂效率。目前合成生物 学可合成的大宗化学品仅几十种,在整体基础化学品中的占比还非 常有限,还无法颠覆性替代传统化工,但在部分领域有比较好的应 用场景,具有战略与商业角度的优势,生物制造未来提升空间巨 大。 ● Al 赋能上游+政策推动落地,合成生物学东风将至 当前,国际合成生物学优势力量主要分布在美、欧等地,其政策对 我国来说具备一定参考意义,国内也正 ...

一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海凯赛生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]1439 号）同意注册，公司于 2020 年向社会公开发行人民币普通股 41,668,198 股，每股面值人民币 1.00 元，每股 发行价为人民币 133.45 元，合计募集资金人民币 556,062.10 万元，扣除各项发 行费用（不含增值税）人民币 28,062.72 万元后，募集资金净额为 527,999.38 万 元。上述募集资金已全部到位，并由天健会计师事务所（特殊普通合伙）验证 并出具"天健验[2020]3-68 号"《验资报告》。公司已按相关规定对募集资金进 行专户存储，并与保荐机构、存放募集资金的银行签署了募集资金三方监管协 议。 二、募集资金投资项目情况 根据公司《首次公开发行股票并在科创板上市招股说明书》披露，公司本 次公开发行股票募集资金投资项目及募集资金使用计划具体如下： 中信证券股份有限公司关于 上海凯赛生物技术股份有限公司将部分募投项目 节余募集资金永久补充流动资金的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为上海 凯 ...